REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Regeneron Announces Investor Conference Presentations

23 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention

22 Aug 2023 13:15:41 By Nasdaq GlobeNewswire

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

18 Aug 2023 17:35:00 By Nasdaq GlobeNewswire

Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease

18 Aug 2023 12:43:19 By Nasdaq GlobeNewswire

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

17 Aug 2023 07:30:11 By Nasdaq GlobeNewswire

Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration

10 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs

09 Aug 2023 06:30:53 By Nasdaq GlobeNewswire

Regeneron Reports Second Quarter 2023 Financial and Operating Results

03 Aug 2023 05:30:01 By Nasdaq GlobeNewswire

Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation

01 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

29 Jul 2023 13:25:00 By Nasdaq GlobeNewswire